Indefinite Delivery Contract SPE2DR25D1116

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DR25D1002, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, is a single-award contract valued at $9,999,999,999 running through December 31, 2036. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes,...
The Indefinite Delivery Contract (IDC) SPE2DR25D6035 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, is a single-award IDC with a period of performance through December 31, 2036. The purpose of this IDC is to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support, including...
This Indefinite Delivery Contract (IDC) award, valued at $999,999,999, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses a broad spectrum of critical medical commodities including...
The Indefinite Delivery Contract (IDC) SPE2DR25D7910 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a period of performance through December 2026 and is intended to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and...
The Indefinite Delivery Contract (IDC) SPE2DR25D2105 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, covers the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines,...
The Indefinite Delivery Contract (IDC) SPE2DR25D7062 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,999,999,999 IDC, running through December 2036, is a prime vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The underlying solicitation, known as the...
The Indefinite Delivery Contract (IDC) SPE2DU25D5117 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $999,999,999 and runs through December 2036, serving as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes...
The Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp is a comprehensive pharmaceutical and medical supply contract valued at $999,999,999 through November 2026. This single-award IDC serves as the primary vehicle for providing a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs,...
The Indefinite Delivery Contract (IDC) SPE2DR25D2206 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 contract, running through December 2036, is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, U.S. Coast...
The Indefinite Delivery Contract (IDC) SPE2DU25D5141 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide worldwide pharmaceutical support to various DoD customers. The $999,999,999 contract has a 30-month base period and three 30-month option periods, totaling an estimated value of $30.3 billion. This IDC aims to establish Pharmaceutical Prime Vendor Global Program Generation V...

The Indefinite Delivery Contract (IDC) SPE2DR25D1116 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 IDC has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

The original solicitation indicates DLA Troop Support plans to establish multiple Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, U.S. Coast Guard, and U.S. Naval Fleet. The procurement covers a broad array of medical commodities such as specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. Awards will be made on a regional basis with at least three different contractors selected, ensuring resiliency and access to vital pharmaceuticals during contingencies or natural disasters. This unrestricted, Lowest Price Technically Acceptable acquisition has an estimated total value of $30.3 billion.

Generated 6/6/25, 9:42 AM